5-Amino-1MQ.

NNMT inhibitor — investigational support for metabolic flexibility and fat oxidation.

Select strengthPer-vial price

Quantity

Total

€50.00· 1 vial

Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.

✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
✓Patient-named prescription only — dispensed against a valid Rx.
✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
✓Cold-chain shipping across EU/EEA — 2–5 working days.

Overview

About 5-Amino-1MQ.

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Inhibition of NNMT preserves cellular NAD+ availability and SAM (S-adenosyl methionine) pools.

Clinical evidence in humans is limited; the molecule is mostly preclinical. Use is investigational and physician-monitored.

Mechanism of action

NNMT consumes methyl groups from SAM to methylate nicotinamide. In obese adipose tissue, elevated NNMT depletes cellular methyl donors and shifts metabolism toward fat storage. 5-Amino-1MQ inhibits NNMT, restoring metabolic flexibility and increasing fatty-acid oxidation in white adipose tissue.

Posology · for information only

Subcutaneous injection, typically 50–150 mg daily in research settings. Magistral protocols start lower and titrate.

Your physician sets the prescription. This is descriptive information, not a self-administration guide.

Storage

Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.

Evidence basePreclinical evidence

Indications studied

Metabolic flexibility (preclinical)Adjunct in metabolic protocols

Identification & specifications

INN / Name: 5-Amino-1MQ
Form: Lyophilised vial · subcutaneous injection
Strength: 10mg vial
Manufacturing: EU-GMP Annex 1 · Grade A/B
Endotoxins: European Pharmacopoeia 2.6.14 · LAL assay
Identity & purity: HPLC + MS · > 98%
Cold chain: Validated 2–8 °C, monitored end-to-end
Regulatory basis: Directive 2001/83/EC · Article 5(1)

Logistics

2–5 working days

EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.

Legal status

Magistral preparation

Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.

Cross-border

EU prescription recognition

Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.

Same therapeutic axis

Within Weight Management.

All Weight Management preparations